Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SARS-CoV-2 Spike Protein's Structural Dynamics Affect the Activity of the Bebtelovimab Antibody.

Journal of chemical information and modeling - 8 Jun 2026

Mansur Maher, Hong Huixiao, Singh Sachleen, Liu Zhichao, Azevedo Marli, Li Dongying, Knox Bridgett, Hasan Md Rashedul, Tong Weida, Baudry Jerome, Ning Baitang

Abstract excerpt

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) therapeutic monoclonal antibody bebtelovimab (BEB) was designed to target the spike protein of SARS-CoV-2 and block its entry into host cells via the angiotensin-converting enzyme 2 (ACE2) receptor. In this study, we used molecular modeling to predict interactions of six clinically observed viral S-protein mutants with human ACE2, as well as BEB. We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiotensin-Converting Enzyme 2
Share to Antibodies, Monoclonal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Monoclonal, Humanized

Share to Molecular Dynamics Simulation

Share to Mutation

Share to Protein Binding

Share to SARS-CoV-2

Share to Spike Glycoprotein, Coronavirus

Source

Identifiers

PMID: 42202234
DOI: 10.1021/acs.jcim.6c00679

Genes

ACE2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SARS-CoV-2 Spike Protein's Structural Dynamics Affect the Activity of the Bebtelovimab Antibody.PMID 42202234Read ↗

SARS-CoV-2 variants and bebtelovimab: immune escape mechanisms revealed by computational studies.Semantic proximity Read ↗

SARS-CoV-2: Recent Variants and Clinical Efficacy of Antibody-Based Therapy.Semantic proximity Read ↗

Structural changes in the SARS-CoV-2 spike E406W mutant escaping a clinical monoclonal antibody cocktailSemantic proximity Read ↗

Structural insight into antibody evasion of SARS-CoV-2 omicron variantSemantic proximity Read ↗

Impact of the N501Y substitution of SARS-CoV-2 Spike on neutralizing monoclonal antibodies targeting diverse epitopes.Semantic proximity Read ↗

Impact of BA.1, BA.2, and BA.4/BA.5 Omicron mutations on therapeutic monoclonal antibodies.Semantic proximity Read ↗

The SARS-CoV-2 B.1.618 variant slightly alters the spike RBD–ACE2 binding affinity and is an antibody escaping variant: a computational structural perspectiveSemantic proximity Read ↗

Comparative Binding Ability of Human Monoclonal Antibodies against Omicron Variants of SARS-CoV-2: An In Silico InvestigationSemantic proximity Read ↗

A structure-function analysis shows SARS-CoV-2 BA.2.86 balances antibody escape and ACE2 affinity.Semantic proximity Read ↗

ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodiesSemantic proximity Read ↗

Structural analysis of receptor binding domain mutations in SARS-CoV-2 variants of concern that modulate ACE2 and antibody binding.Semantic proximity Read ↗

Key mechanistic features of the trade-off between antibody escape and host cell binding in the SARS-CoV-2 Omicron variant spike proteinsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.